Show results for
Refine by
Immunotherapies For Cancer Equipment & Supplies In Austria
44 equipment items found
by:Metaclipse Therapeutics Corporation based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a patient’s tumor tissue that Metaclipse modifies with a ‘protein transfer’ method using ...
by:Metaclipse Therapeutics Corporation based inAtlanta, GEORGIA (US) (USA)
Influenza (Target age 65+) and Influenza+ SARS-C0V-2 ...
Manufactured by:MedGenome Inc. based inCounty of New Castle, DELAWARE (USA)
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune ...
Manufactured by:Treos Bio Limited based inLondon, UNITED KINGDOM
PEPI Panel – A unique approach for personalized cancer immunotherapy generation. Our Peptide Library (PEPI Panel) currently contains 3,286 proprietary, immunogenic peptide fragments from 184 tumor antigens associated with 19 cancer indications that induce immune responses in the largest subpopulation of subjects, based on HLA genotype ...
Manufactured by:MV BioTherapeutics SA based inBellinzona, SWITZERLAND
MV010/MV004, in cancer immunotherapy • Significant increase of tumor specific cytotoxic T cells infiltrating the tumor microenvironment by combining MV010/MV004 to anti-PD-L1 administration in murine models. • Significantly improved tumor eradication and resistance to subsequent grafting and improved survival in murine models. ...
by:Calviri based inPhoenix, ARIZONA (USA)
Calviri’s immunotherapy diagnostic is a huge leap forward in predicting therapy outcomes compared to current available ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso5 is a discovery-stage program leveraging a specific keystone gut bacteria (undisclosed) to potentiate the effects of Immune Checkpoint Blockade (ICB) drugs. The field of cancer therapy has been revolutionized by the use of immunotherapy. The microbiome breakthrough science today paves the way for innovative biotherapies to potentiate the effectiveness of ...
by:Enveric Biosciences, Inc. based inNaples, FLORIDA (USA)
Enveric Biosciences seeks to advance novel combinations of CBD with chemotherapeutic agents and immunotherapies. Preclinical data suggests combination therapies may improve the activity of certain chemotherapies or cancer immunotherapies, potentially enabling more potent or longer-lasting therapeutic effects. In addition, combination therapies ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
OSE’s R&D team and its academic partners have characterized the myeloid checkpoint CLEC-1 (a C-type lectin receptor) as a new therapeutic target in immuno-oncology and identified monoclonal antibody antagonists blocking this novel “Don’t Eat Me” signal. CLEC-1 antagonist monoclonal antibodies have been identified as an innovative cancer ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK00X: Kiadis is evaluating preclinical programs with K-NK-cell therapies for the treatment of hematologic and solid ...
Manufactured by:Treos Bio Limited based inLondon, UNITED KINGDOM
Off-the-shelf products contain 6-12 shared tumor-specific antigen derived peptides optimized for a population. They are personalized with a candidate companion diagnostic test (CDx). In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high proportion of patients, without need of biopsy. Phase 1 clinical study ...
Manufactured by:Exscientia based inOxford, UNITED KINGDOM
EXS21546 is our peripherally-restricted and selective antagonist of the Adenosine A2a Receptor. It is designed for anti-cancer immunotherapy, combatting adenosine related immunosuppressive effects, through T-cell ...
Manufactured by:JPT Peptide Technologies GmbH based inBerlin, GERMANY
Neo-epitopes are important targets for individualized cancer immunotherapy. Recent advancements in next generation sequencing and bioinformatic approaches to predict immunogenicity of neo-epitopes improved target selection for therapy. However, in many cases only a fraction of predicted epitopes generate a specific T-cell response. ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK003: A phase 1 study evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML). This study was designed based on promising clinical proof-of-concept data from two studies, one at MD Anderson Cancer Center and one at HCPA in ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
A novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets being developed by the Company to fight primary and secondary resistance mechanisms developed by cancers to evade checkpoint inhibitor ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Ombipepimut-S Emulsion (DSP-7888) is an investigational immunotherapeutic cancer vaccine containing 2 peptides that induce WT1-specific cytotoxic T lymphocytes (WT1-CTLs) and helper T cells to attack WT1-expressing cancerous cells found in various types of hematologic malignancies and solid tumors.1,2 Researchers have identified that adding helper T-cell–inducing peptides improved ...
Manufactured by:Virasoft Inc. based inSarıyer, TURKEY
Programmed cell death protein 1 (PD-1; also called CD279) is one of the co-inhibitory receptors that is expressed on the surface of antigen-stimulated T cells [1]. Normally, PD-L1 expression can be detected on hematopoietic cells including T cells, B cells, macrophages, dendritic cells, mast cells and healthy tissue cells. But PD-L1 can be expressed by tumor cells and tumor stroma. Interaction ...
Manufactured by:OncoQR ML GmbH based inBreitenfurt, AUSTRIA
Cancer cells have the ability to escape our immune system´s defenses – by outsmarting checkpoint molecules on our immune cells. For more than three decades, science and industry have been working to overcome cancer’s tricky battle ...
Manufactured by:Caprico Biotechnologies, Inc. (CBI) based inNorcross, GEORGIA (US) (USA)
The clone 528, a mouse monoclonal antibody, specifically reacts with an epitope of the ~170 kDa extracellular protein domain of human epidermal growth factor receptor or commonly known as EGFR. Physiologically EGFR is expressed in the skin, gastrointestinal system, kidney, and other normal tissues as well as aberrantly over expresses in epithelial cancer cells of lung, pancreas, colon, breast, ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES002’s dual ATP-adenosine mechanism is a potentially powerful TME regulator and transformative cancer immunotherapy. In preclinical studies ES002 demonstrated significant single agent anti-tumor activity as well as an excellent tolerability profile. ES002 has also shown superior enzymatic inhibition and binding ...